{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:49:47Z","timestamp":1773330587735,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"6","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.bcp.2013.07.015","type":"journal-article","created":{"date-parts":[[2013,8,5]],"date-time":"2013-08-05T22:30:17Z","timestamp":1375741817000},"page":"782-790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice"],"prefix":"10.1016","volume":"86","author":[{"given":"Sun-Don","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ha-Neui","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Jong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soon Jung","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyunil","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zang Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2013.07.015_bib0005","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1600-065X.2009.00821.x","article-title":"Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation","volume":"231","author":"Negishi-Koga","year":"2009","journal-title":"Immunological Reviews"},{"key":"10.1016\/j.bcp.2013.07.015_bib0010","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1084\/jem.190.12.1741","article-title":"Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors","volume":"190","author":"Arai","year":"1999","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/j.bcp.2013.07.015_bib0015","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2013.07.015_bib0020","doi-asserted-by":"crossref","first-page":"18245","DOI":"10.1074\/jbc.M610701200","article-title":"NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1","volume":"282","author":"Yamashita","year":"2007","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.bcp.2013.07.015_bib0025","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1534-5807(02)00369-6","article-title":"Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts","volume":"3","author":"Takayanagi","year":"2002","journal-title":"Developmental Cell"},{"key":"10.1016\/j.bcp.2013.07.015_bib0030","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/nature02444","article-title":"Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis","volume":"428","author":"Koga","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2013.07.015_bib0035","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.cell.2007.12.037","article-title":"Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals","volume":"132","author":"Shinohara","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2013.07.015_bib0040","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/nm1515","article-title":"Regulation of osteoclast differentiation and function by the CaMK\u2013CREB pathway","volume":"12","author":"Sato","year":"2006","journal-title":"Nature Medicine"},{"key":"10.1016\/j.bcp.2013.07.015_bib0045","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood-2009-08-237404","article-title":"Dysregulation of bone remodeling by imatinib mesylate","volume":"115","author":"Vandyke","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2013.07.015_bib0050","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa051140","article-title":"Altered bone and mineral metabolism in patients receiving imatinib mesylate","volume":"354","author":"Berman","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.bcp.2013.07.015_bib0055","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1182\/blood-2007-07-104281","article-title":"Long-term imatinib therapy promotes bone formation in CML patients","volume":"111","author":"Fitter","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2013.07.015_bib0060","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1359\/jbmr.070719","article-title":"Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms","volume":"22","author":"O'Sullivan","year":"2007","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.bcp.2013.07.015_bib0065","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/sj.leu.2404944","article-title":"Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis","volume":"22","author":"Brownlow","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2013.07.015_bib0070","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1182\/blood-2005-09-3568","article-title":"Imatinib as a potential antiresorptive therapy for bone disease","volume":"107","author":"Dewar","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2013.07.015_bib0075","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00774-006-0684-1","article-title":"Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA)","volume":"24","author":"Ando","year":"2006","journal-title":"Journal of Bone and Mineral Metabolism"},{"key":"10.1016\/j.bcp.2013.07.015_bib0080","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/0002-8703(92)90792-T","article-title":"Effects of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty","volume":"123","author":"Okamoto","year":"1992","journal-title":"American Heart Journal"},{"key":"10.1016\/j.bcp.2013.07.015_bib0085","first-page":"1369","article-title":"Trapidil inhibits monocyte chemoattractant protein-1 and macrophage accumulation after balloon arterial injury in rabbits","volume":"79","author":"Poon","year":"1999","journal-title":"Laboratory Investigation"},{"key":"10.1016\/j.bcp.2013.07.015_bib0090","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/S0024-3205(99)00547-0","article-title":"Inhibitory effects of trapidil on PDGF signaling in balloon-injured rat carotid artery","volume":"65","author":"Deguchi","year":"1999","journal-title":"Life Sciences"},{"key":"10.1016\/j.bcp.2013.07.015_bib0095","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0014-5793(84)81119-9","article-title":"Decrease of platelet aggregation and spreading via inhibition of the cAMP phosphodiesterase by trapidil","volume":"172","author":"Mazurov","year":"1984","journal-title":"FEBS Letters"},{"key":"10.1016\/j.bcp.2013.07.015_bib0100","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0161-4630(81)90151-8","article-title":"Effects of trapidil on thromboxane A2-induced aggregation of platelets, ischemic changes in heart and biosynthesis of thromboxane A2","volume":"6","author":"Ohnishi","year":"1981","journal-title":"Prostaglandins and Medicine"},{"key":"10.1016\/j.bcp.2013.07.015_bib0105","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1006\/clim.1999.4796","article-title":"Inhibition of the CD40 pathway of monocyte activation by triazolopyrimidine","volume":"93","author":"Zhou","year":"1999","journal-title":"Clinical Immunology"},{"key":"10.1016\/j.bcp.2013.07.015_bib0110","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S0008-6363(03)00261-X","article-title":"Trapidil protects ischemic hearts from reperfusion injury by stimulating PKAII activity","volume":"58","author":"Sichelschmidt","year":"2003","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.bcp.2013.07.015_bib0115","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1210\/en.2002-221000","article-title":"Triazolopyrimidine (trapidil), a platelet-derived growth factor antagonist, inhibits parathyroid bone disease in an animal model for chronic hyperparathyroidism","volume":"144","author":"Lotinun","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2013.07.015_bib0120","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/jbmr.49","article-title":"The role of mast cells in parathyroid bone disease","volume":"25","author":"Turner","year":"2010","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.bcp.2013.07.015_bib0125","doi-asserted-by":"crossref","first-page":"13725","DOI":"10.1074\/jbc.M806941200","article-title":"Trolox prevents osteoclastogenesis by suppressing RANKL expression and signaling","volume":"284","author":"Lee","year":"2009","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.bcp.2013.07.015_bib0130","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejphar.2012.07.034","article-title":"MS-275, a benzamide histone deacetylase inhibitor, prevents osteoclastogenesis by down-regulating c-Fos expression and suppresses bone loss in mice","volume":"691","author":"Kim","year":"2012","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.bcp.2013.07.015_bib0135","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nri2062","article-title":"Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems","volume":"7","author":"Takayanagi","year":"2007","journal-title":"Nature Reviews Immunology"},{"key":"10.1016\/j.bcp.2013.07.015_bib0140","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/mol.107.034173","article-title":"Suppression of osteoclastogenesis by N,N-dimethyl-d-erythro-sphingosine: a sphingosine kinase inhibition-independent action","volume":"72","author":"Kim","year":"2007","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.bcp.2013.07.015_bib0145","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.bbrc.2006.10.011","article-title":"Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway","volume":"351","author":"Huang","year":"2006","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.bcp.2013.07.015_bib0150","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1254\/jjp.90.328","article-title":"Possible involvement of suppression of Th2 differentiation in the anti-allergic effect of Sho-seiryu-to in mice","volume":"90","author":"Ikeda","year":"2002","journal-title":"Japanese Journal of Pharmacology"},{"key":"10.1016\/j.bcp.2013.07.015_bib0155","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4049\/jimmunol.1101254","article-title":"Akt induces osteoclast differentiation through regulating the GSK3beta\/NFATc1 signaling cascade","volume":"188","author":"Moon","year":"2012","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.bcp.2013.07.015_bib0160","doi-asserted-by":"crossref","first-page":"7460","DOI":"10.4049\/jimmunol.1000885","article-title":"Pim-1 regulates RANKL-induced osteoclastogenesis via NF-kappaB activation and NFATc1 induction","volume":"185","author":"Kim","year":"2010","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.bcp.2013.07.015_bib0165","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00383-005-1542-2","article-title":"Protective effects of trapidil in lung after abdominal aorta induced ischemia\u2013reperfusion injury: an experimental study","volume":"21","author":"Somuncu","year":"2005","journal-title":"Pediatric Surgery International"},{"key":"10.1016\/j.bcp.2013.07.015_bib0170","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.burns.2005.04.013","article-title":"Protective effect of trapidil against oxidative organ damage in burn injury","volume":"31","author":"Avlan","year":"2005","journal-title":"Burns"},{"key":"10.1016\/j.bcp.2013.07.015_bib0175","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1006\/phrs.2001.0864","article-title":"Effect of trapidil, an antiplatelet and vasodilator agent on gentamicin-induced nephrotoxicity in rats","volume":"44","author":"Buyukafsar","year":"2001","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.bcp.2013.07.015_bib0180","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2013.07.015_bib0185","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.bone.2011.04.014","article-title":"The skeletal effects of the tyrosine kinase inhibitor nilotinib","volume":"49","author":"O'Sullivan","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2013.07.015_bib0190","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0896-6273(00)80245-7","article-title":"Spatiotemporal dynamics of CREB phosphorylation: transient versus sustained phosphorylation in the developing striatum","volume":"17","author":"Liu","year":"1996","journal-title":"Neuron"},{"key":"10.1016\/j.bcp.2013.07.015_bib0195","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1073\/pnas.0800642105","article-title":"Osteoblasts induce Ca2+ oscillation-independent NFATc1 activation during osteoclastogenesis","volume":"105","author":"Kuroda","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.bcp.2013.07.015_bib0200","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S0140-6736(10)62349-5","article-title":"Osteoporosis: now and the future","volume":"377","author":"Rachner","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2013.07.015_bib0205","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S8756-3282(01)00414-8","article-title":"Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles","volume":"28","author":"Mashiba","year":"2001","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2013.07.015_bib0210","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1359\/jbmr.2000.15.4.613","article-title":"Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib","volume":"15","author":"Mashiba","year":"2000","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.bcp.2013.07.015_bib0215","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","article-title":"Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis","volume":"100","author":"Chavassieux","year":"1997","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.bcp.2013.07.015_bib0220","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S8756-3282(02)00869-4","article-title":"Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis","volume":"31","author":"Eriksen","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2013.07.015_bib0225","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1\u201334)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.bcp.2013.07.015_bib0230","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","article-title":"The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis","volume":"350","author":"Meunier","year":"2004","journal-title":"New England Journal of Medicine"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295213004516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295213004516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,14]],"date-time":"2018-10-14T00:30:38Z","timestamp":1539477038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295213004516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0006295213004516"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2013.07.015","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2013.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}